Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
CervoMed Inc.
Last earnings -11.6% on 2026-05-18
Conservative balance sheet (liabilities/equity 0.26x); but revenue fell -58.9% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
CervoMed Inc. shows $4.01M in FY2025 revenue (-58.9% YoY), a -673.1% net margin, and -148.0% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001053691, latest 10-Q filed 2026-05-15) · EODHD · rules-based read · as of 6/17/2026, 2:12:41 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $7.14M | $9.74M | $4.01M |
| Gross profit | — | — | — | — | — |
| Operating income | -$24.7M | -$3.48M | -$7.81M | -$18.2M | -$28.3M |
| Net income | -$24.1M | -$5.80M | -$2.17M | -$16.3M | -$27.0M |
| Diluted EPS | $1,946,859.00 | $2,038,891.00 | — | — | — |
| Net margin | — | — | -30.4% | -167.3% | -673.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Last 90 days: 1 open-market buy · 0 sales
| 2026-06-11 | BOGER JOSHUA S Director | Buy | 955K @ $3.14 | $3.00M |